Literature DB >> 27416775

Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Jonathan J Hogan1, Brendan M Weiss2.   

Abstract

The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not associated with systemic lymphoma or overt multiple myeloma. The prevailing hypothesis is that the pathogenic paraproteins in MGRS are produced by underlying B cell or plasma cell clones. However, in the MGRS literature, the yield of detecting a clone has been variable, and progression to ESRD is common. Here, we present an "onco-nephrologic" approach to the MGRS disorders by highlighting recent advances in lymphoma and multiple myeloma that can be used in the evaluation and management of these patients.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  B-Lymphocytes; Chronic; Humans; Kidney Failure; Lymphoma; Myeloma Proteins; Paraproteinemias; Paraproteins; Plasma Cells; glomerular disease; kidney; multiple myeloma; multiple myeloma M-proteins; proteinuria

Mesh：

Substances：

Year:  2016        PMID： 27416775      PMCID： PMC5012477          DOI： 10.2215/CJN.03160316

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


  64 in total

1.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

2.  Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.

Authors:  Neil E Kay; Wenting Wu; Brian Kabat; Betsy LaPlant; Thomas S Lin; John C Byrd; Diane F Jelinek; Michael R Grever; Clive S Zent; Timothy G Call; Tait D Shanafelt
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

3.  Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

Authors:  Wolfram Pönisch; Marc Andrea; Ina Wagner; Doreen Hammerschmidt; Ute Kreibich; Andreas Schwarzer; Thomas Zehrfeld; Maik Schwarz; Cornelia Winkelmann; Sirak Petros; Anette Bachmann; Tom Lindner; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-13       Impact factor: 4.553

4.  Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Bercedis L Peterson; John G Gribben; Vicki A Morrison; Kanti R Rai; Richard A Larson; John C Byrd
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

5.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

6.  Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

Authors:  Mathias Rummel; Ulrich Kaiser; Christina Balser; Martina Stauch; Wolfram Brugger; Manfred Welslau; Norbert Niederle; Christoph Losem; Hans-Peter Boeck; Eckhart Weidmann; Ulrich von Gruenhagen; Lothar Mueller; Michael Sandherr; Lars Hahn; Julia Vereshchagina; Frank Kauff; Wolfgang Blau; Axel Hinke; Juergen Barth
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

7.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

8.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

Review 9.  How I treat monoclonal gammopathy of renal significance (MGRS).

Authors:  Jean-Paul Fermand; Frank Bridoux; Robert A Kyle; Efstathios Kastritis; Brendan M Weiss; Mark A Cook; Mark T Drayson; Angela Dispenzieri; Nelson Leung
Journal:  Blood       Date:  2013-10-09       Impact factor: 22.113

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  12 in total

Review 1.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

2.  A Case of Monoclonal Gammopathy of Renal Significance.

Authors:  Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-18       Impact factor: 8.237

3.  Monoclonal Gammopathies and Kidney Disease: Searching for Significance.

Authors:  Christina Hao Wang; Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

Review 4.  Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.

Authors:  Mariana Ciocchini; Jorge Arbelbide; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2017-04-19       Impact factor: 2.370

5.  Proliferative glomerulonephritis with monoclonal immunoglobulin deposits of lambda chains.

Authors:  Muhammad A Panezai; Pingchaun Zhang; Gates B Colbert
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-12

6.  Association of Monoclonal Gammopathy with Progression to ESKD among US Veterans.

Authors:  Nicholas Burwick; Scott V Adams; Jeffrey A Todd-Stenberg; Nilka Rios Burrows; Meda E Pavkov; Ann M O'Hare
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

Review 7.  Monoclonal gammopathy of renal significance: Diagnostic workup.

Authors:  Sofia O Correia; Sofia Santos; Jorge Malheiro; António Cabrita; La Salete Martins; Josefina Santos
Journal:  World J Nephrol       Date:  2017-03-06

8.  Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease.

Authors:  Gaetano Alfano; Alice Delrio; Francesco Fontana; Giacomo Mori; Silvia Cazzato; Annachiara Ferrari; Rossella Perrone; Silvia Giovanella; Giulia Ligabue; Riccardo Magistroni; Gianni Cappelli
Journal:  Int J Nephrol       Date:  2021-05-12

9.  Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance.

Authors:  Bin Xu; Yi Tang; Jianfeng Zhou; Peiling Zhang; Huijun Li
Journal:  Oncotarget       Date:  2017-07-19

10.  Cyclophosphamide, bortezomib and dexamethasone (CyBorD): a promising regimen for renal light chain deposit disease.

Authors:  Arunima Dutta; Kavitha Kesari; Trevor Singh
Journal:  BMJ Case Rep       Date:  2020-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.